
Women with incurable breast cancer in England and Wales will not be offered a life-extending drug on the health service after talks between the NHS spending watchdog and its manufacturer ended without an agreement on price for the third time.
The National Institute for Health and Care Excellence (Nice) said it is “extremely disappointed” it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu.